2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

2:30PM-4:00PM: Abstract Number: 3052

Causes of Death for Patients with Rheumatoid Arthritis

ARHP V: Epidemiology and Public Health

2:30PM-4:00PM: Abstract Number: 3035

Characterization of DC-STAMP+ T Cells, a CD3+CD4+ T Cell Subset Uniquely Present in Patients with Psoriatic Disease

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology I

2:30PM-4:00PM: Abstract Number: 2988

Cigarette Smoking Increases the Risk of Anti-Double-Stranded DNA Positive SLE Among Women in the Nurses’ Health Studies

2016 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

2:30PM-4:00PM: Abstract Number: 3020

Citrullination of Inhibitor of DNA Binding-1 at Specific Locations Leads to Autoantigenicity in Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 3008

Clinical Factors Associated with Non-Response to Methotrexate in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Response to Treatment Consortium

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 3012

Clinical Predictors of TNF-Inhibitor Free Disease Control in Patients with Rheumatoid Arthritis after Stopping TNFi Treatment: Results from a Dutch Multicentre Pragmatic Open-Label Randomized Controlled Trial.

Rheumatoid Arthritis – Clinical Aspects IV: Managing Patients in Remission

2:30PM-4:00PM: Abstract Number: 3043

Dense Genotyping of Immune Related Loci in a Multi-Ethnic Behçet’s Disease Cohort Identifies Genetic Associations in a Long Noncoding RNA Near QSOX2, RASIP1/FUT2, and IL12A-AS1

Vasculitis III: Pathogenic Mechanisms

2:30PM-4:00PM: Abstract Number: 3005

Development and Initial Validation of the “MH Score”, a New Diagnostic Tool That Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome

Pediatric Rheumatology – Clinical and Therapeutic Aspects II: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 3047

Diabetes and BMI Modify the Association Between Painful Hip OA and All-Cause Mortality

ARHP V: Epidemiology and Public Health

2:30PM-4:00PM: Abstract Number: 3002

Does Morbid Obesity Negatively Affect Patient Reported Outcomes Following Total Knee Arthroplasty?

Orthopedics, Low Back Pain and Rehabilitation

2:30PM-4:00PM: Abstract Number: 3013

Dose Reduction or Discontinuation of Biological Therapy in Patients with Rheumatoid Arthritis in Remission – 1-Year Results of a Guideline-Directed Longitudinal Cohort Study

Rheumatoid Arthritis – Clinical Aspects IV: Managing Patients in Remission

2:30PM-4:00PM: Abstract Number: 3017

Elevated Neutrophil Extracellular Trap Levels Correlate with Anti-CCP3-IgG and Anti-CCP3-IgA Levels in the Sputum of Individuals at-Risk for Future Rheumatoid Arthritis

Rheumatoid Arthritis – Human Etiology and Pathogenesis I

2:30PM-4:00PM: Abstract Number: 3044

Endothelin 1 Induces a Myofibroblastic Phenotype in Vascular Smooth Muscle Cells. A Mechanism Potentially Contributing to Vascular Remodeling and Intimal Hyperplasia in Giant Cell Arteritis

Vasculitis III: Pathogenic Mechanisms

2:30PM-4:00PM: Abstract Number: 3038

Enumeration and Preliminary Characterisation of Peri-Entheseal Bone Type 3 Innate Lymphoid Cells

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology I

2:30PM-4:00PM: Abstract Number: 3030

Evidence of Inflammasome Activation in the Peripheral Blood and Salivary Gland Tissues of Primary Sjögren’s Syndrome Patients: Correlation with Clinical Indices of Severe Disease and Lymphoma Development

Sjögren's Syndrome I: Clinical Insights

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].